David A. Roth
2019 - Syros Pharmaceuticals
In 2019, David A. Roth earned a total compensation of $1.6M as Chief Medical Officer at Syros Pharmaceuticals, a 35% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $189,000 |
|---|---|
| Option Awards | $383,023 |
| Salary | $452,115 |
| Stock Awards | $583,770 |
| Other | $360 |
| Total | $1,608,268 |
Roth received $583.8K in stock awards, accounting for 36% of the total pay in 2019.
Roth also received $189K in non-equity incentive plan, $383K in option awards, $452.1K in salary and $360 in other compensation.
Rankings
In 2019, David A. Roth's compensation ranked 6,995th out of 13,971 executives tracked by ExecPay. In other words, Roth earned more than 49.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,995 out of 13,971 | 50th |
Division Manufacturing | 2,679 out of 5,695 | 53rd |
Major group Chemicals And Allied Products | 984 out of 2,194 | 55th |
Industry group Drugs | 833 out of 1,880 | 56th |
Industry Pharmaceutical Preparations | 612 out of 1,392 | 56th |
Source: SEC filing on April 28, 2020.
Roth's colleagues
We found two more compensation records of executives who worked with David A. Roth at Syros Pharmaceuticals in 2019.
News
Syros Pharmaceuticals CEO Nancy Simonian's 2022 pay rises 12% to $3.5M
April 21, 2023
Syros Pharmaceuticals CEO Nancy Simonian's 2021 pay jumps 23% to $3.1M
April 21, 2022
Syros Pharmaceuticals CEO Nancy Simonian's 2020 pay falls 30% to $2.5M
April 29, 2021
Syros Pharmaceuticals CEO Nancy Simonian's 2019 pay rises 19% to $3.6M
April 28, 2020
Syros Pharmaceuticals CEO Nancy Simonian's 2018 pay jumps 36% to $3M
April 25, 2019